Astellas Pharma Inc
Clinical trials sponsored by Astellas Pharma Inc, explained in plain language.
-
New targeted drug shows promise against tough leukemia
Disease control OngoingThis study tested a new drug called ASP2215 against standard chemotherapy in 276 adults with a specific genetic form of acute myeloid leukemia (FLT3 mutation) that had come back or not responded to initial treatment. The goal was to see if ASP2215 helped people live longer (overa…
Phase: PHASE3 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated May 15, 2026 11:58 UTC
-
New drug targets Hard-to-Treat cancers with KRAS G12D mutation
Disease control OngoingThis early-stage study tests a new drug called ASP4396 in adults with advanced solid tumors that have a specific change in the KRAS gene (G12D mutation). The main goals are to check safety, find a good dose, and see how the body handles the drug. Participants receive the drug thr…
Phase: PHASE1 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated May 15, 2026 11:56 UTC